Epizyme Competitors and Similar CompaniesClear all
Epizyme's competitors and similar companies include Imago BioSciences, Ascentage Pharma, Achilles Therapeutics and X4 Pharmaceuticals.
 Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. |  Imago BioSciences Imago BioSciences is a clinical-stage biotechnology company developing treatments for myeloid diseases. |  Ascentage Pharma Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies. |  Achilles Therapeutics Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. |  X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services. | |
Founding Date | Founding Date 2007 | Founding Date 2012 | Founding Date 2017 | Founding Date 2016 | Founding Date 2010 |
Type | Type Public | Type Subsidiary | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ | Locations Rahway, US HQ | Locations Suzhou, CN HQ Guangzhou Shi, CN Suzhou Shi, CN Taizhou, CN Rockville, US | Locations London, GB HQ Stevenage, GB | Locations Boston, US HQ Wien, AT |
Employees | Employees 20364% increase | Employees 2759% increase | Employees 567 | Employees 695% decrease | Employees 1005% increase |
Valuation ($) | Valuation ($) 250.8 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 83.9 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $37.4m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) ¥574.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $6.5m (FY, 2025) |
Cost of goods | Cost of goods $10.5m (FY, 2021) | Cost of goods N/A | Cost of goods ¥48.9m (FY, 2025) | Cost of goods N/A | Cost of goods $5.8m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit ¥546.6m (FY, 2025) | Gross profit N/A | Gross profit $743k (FY, 2025) |
Net income | Net income ($251.1m) (FY, 2021) | Net income ($42.3m) (FY, 2021) | Net income (¥1.2b) (FY, 2025) | Net income ($69.7m) (FY, 2023) | Net income N/A |
Operating ⚠ | |||||
Trademarks (US) | Trademarks (US) N/A | Trademarks (US) 1 (May, 2024) | Trademarks (US) N/A | Trademarks (US) 3 (May, 2021) | Trademarks (US) N/A |
Funding | |||||
Total funding raised | Total funding raised $ 51.5m | Total funding raised $ 146.5m | Total funding raised $ 237.5m | Total funding raised $ 138.1m | Total funding raised $ 64.5m |
For sources of this data, please see the company profile
View Company Profiles
Imago BioSciences
HQ
Rahway, US
Imago BioSciences is a clinical-stage biotechnology company developing treatments for myeloid diseases.
View companyAscentage Pharma
HQ
Suzhou, CN
Employees
567
Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies.
View companyAchilles Therapeutics
HQ
London, GB
Employees
69↓ 5% decrease
Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer.
View companyX4 Pharmaceuticals
HQ
Boston, US
Employees
100↑ 5% increase
X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
View company